CN115087461A - 使用pd-1拮抗剂、ilt4拮抗剂和化学治疗剂的组合治疗癌症的方法 - Google Patents

使用pd-1拮抗剂、ilt4拮抗剂和化学治疗剂的组合治疗癌症的方法 Download PDF

Info

Publication number
CN115087461A
CN115087461A CN202080097157.4A CN202080097157A CN115087461A CN 115087461 A CN115087461 A CN 115087461A CN 202080097157 A CN202080097157 A CN 202080097157A CN 115087461 A CN115087461 A CN 115087461A
Authority
CN
China
Prior art keywords
cancer
human
ilt4
monoclonal antibody
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080097157.4A
Other languages
English (en)
Chinese (zh)
Inventor
P·E·布兰迪什
R·A·阿尔图拉
B·皮珀迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme BV
Original Assignee
Merck Sharp and Dohme BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme BV filed Critical Merck Sharp and Dohme BV
Publication of CN115087461A publication Critical patent/CN115087461A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202080097157.4A 2019-12-20 2020-12-16 使用pd-1拮抗剂、ilt4拮抗剂和化学治疗剂的组合治疗癌症的方法 Pending CN115087461A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962951357P 2019-12-20 2019-12-20
US62/951357 2019-12-20
PCT/US2020/065208 WO2021126906A1 (en) 2019-12-20 2020-12-16 Methods for treating cancer using a combination of a pd-1 antagonist, an ilt4 antagonist, and chemotherapeutic agents

Publications (1)

Publication Number Publication Date
CN115087461A true CN115087461A (zh) 2022-09-20

Family

ID=76476667

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080097157.4A Pending CN115087461A (zh) 2019-12-20 2020-12-16 使用pd-1拮抗剂、ilt4拮抗剂和化学治疗剂的组合治疗癌症的方法

Country Status (10)

Country Link
US (1) US20230050449A1 (enExample)
EP (1) EP4076521A4 (enExample)
JP (1) JP2023510132A (enExample)
KR (1) KR20220123017A (enExample)
CN (1) CN115087461A (enExample)
AU (1) AU2020408678A1 (enExample)
BR (1) BR112022012081A2 (enExample)
CA (1) CA3162311A1 (enExample)
MX (1) MX2022007516A (enExample)
WO (1) WO2021126906A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250011453A1 (en) * 2021-07-20 2025-01-09 Merck Sharp & Dohme Llc Methods for treating cancer using a combination of a pd-1 antagonist, an ilt4 antagonist, and chemotherapeutic agents
WO2024120526A1 (zh) * 2022-12-09 2024-06-13 诺纳生物（苏州）有限公司 抗ilt4抗体及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170037132A1 (en) * 2015-07-14 2017-02-09 Bristol-Myers Squibb Company Method of treating cancer using immune checkpoint inhibitor
US20180298096A1 (en) * 2017-04-07 2018-10-18 Merck Sharp & Dohme Corp. Anti-ILT4 Antibodies and Antigen-Binding Fragments
WO2019023482A1 (en) * 2017-07-27 2019-01-31 Regeneron Pharmaceuticals, Inc. ANTI-CTLA-4 ANTIBODIES AND USES THEREOF
WO2019160751A2 (en) * 2018-02-13 2019-08-22 Merck Sharp & Dohme Corp. Methods for treating cancer with anti-pd-1 antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015176033A1 (en) * 2014-05-15 2015-11-19 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
EA202091540A1 (ru) * 2017-12-22 2021-03-22 Джаунс Терапьютикс, Инк. Антитела к lilrb2
WO2019148410A1 (en) * 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1 antibodies
CN113056483B (zh) * 2018-07-09 2025-08-01 戊瑞治疗有限公司 结合到ilt4的抗体
AU2019343131A1 (en) * 2018-09-17 2021-04-29 Icahn School Of Medicine At Mount Sinai Anti-LILRB2 antibodies and methods of use thereof
US20230058779A1 (en) * 2020-01-02 2023-02-23 Merck Sharp & Dohme Llc Combination cancer treatment using a pd-1 antagonist, an ilt4 antagonist, and lenvatinib or salts thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170037132A1 (en) * 2015-07-14 2017-02-09 Bristol-Myers Squibb Company Method of treating cancer using immune checkpoint inhibitor
US20180298096A1 (en) * 2017-04-07 2018-10-18 Merck Sharp & Dohme Corp. Anti-ILT4 Antibodies and Antigen-Binding Fragments
WO2019023482A1 (en) * 2017-07-27 2019-01-31 Regeneron Pharmaceuticals, Inc. ANTI-CTLA-4 ANTIBODIES AND USES THEREOF
CN111133004A (zh) * 2017-07-27 2020-05-08 瑞泽恩制药公司 抗ctla-4抗体和其用途
WO2019160751A2 (en) * 2018-02-13 2019-08-22 Merck Sharp & Dohme Corp. Methods for treating cancer with anti-pd-1 antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RISCHIN等: "A phase III, randomised, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation in patients with high-risk cutaneous squamous cell carcinoma (CSCC)", ANNALS OF ONCOLOGY, vol. 30, 1 October 2019 (2019-10-01), pages 560 *

Also Published As

Publication number Publication date
MX2022007516A (es) 2022-07-05
CA3162311A1 (en) 2021-06-24
US20230050449A1 (en) 2023-02-16
EP4076521A1 (en) 2022-10-26
JP2023510132A (ja) 2023-03-13
EP4076521A4 (en) 2024-01-24
BR112022012081A2 (pt) 2022-08-30
WO2021126906A1 (en) 2021-06-24
KR20220123017A (ko) 2022-09-05
AU2020408678A1 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
US20230058779A1 (en) Combination cancer treatment using a pd-1 antagonist, an ilt4 antagonist, and lenvatinib or salts thereof
US20230365678A1 (en) Dosing regimens of anti-ilt4 antibody or its combination with anti-pd-1 antibody for treating cancer
WO2025002280A1 (en) Combination therapies for the treatment of cancer
CN115087461A (zh) 使用pd-1拮抗剂、ilt4拮抗剂和化学治疗剂的组合治疗癌症的方法
AU2024311205A1 (en) Treatment method and use of pharmaceutical combination containing conjugate
WO2019067332A1 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER THROUGH A COMBINATION OF PROGRAMMED DEATH ANTIBODY ANTIBODIES (PD-1) AND A CXCR2 ANTAGONIST
US20250011453A1 (en) Methods for treating cancer using a combination of a pd-1 antagonist, an ilt4 antagonist, and chemotherapeutic agents
CA3221834A1 (en) Combination therapies for the treatment of non-small cell lung cancer
TW202502382A (zh) 治療組合及其用途和治療方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220920

WD01 Invention patent application deemed withdrawn after publication